These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 19429511)
21. Histamine H3 receptor antagonists: from target identification to drug leads. Bonaventure P; Letavic M; Dugovic C; Wilson S; Aluisio L; Pudiak C; Lord B; Mazur C; Kamme F; Nishino S; Carruthers N; Lovenberg T Biochem Pharmacol; 2007 Apr; 73(8):1084-96. PubMed ID: 17129577 [TBL] [Abstract][Full Text] [Related]
22. Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121. Pan JB; Yao BB; Miller TR; Kroeger PE; Bennani YL; Komater VA; Esbenshade TA; Hancock AA; Decker MW; Fox GB Life Sci; 2006 Aug; 79(14):1366-79. PubMed ID: 16730751 [TBL] [Abstract][Full Text] [Related]
23. The human histamine H3 receptor couples to GIRK channels in Xenopus oocytes. Sahlholm K; Nilsson J; Marcellino D; Fuxe K; Arhem P Eur J Pharmacol; 2007 Jul; 567(3):206-10. PubMed ID: 17537431 [TBL] [Abstract][Full Text] [Related]
24. Molecular aspects of the histamine H3 receptor. Bongers G; Bakker RA; Leurs R Biochem Pharmacol; 2007 Apr; 73(8):1195-204. PubMed ID: 17276412 [TBL] [Abstract][Full Text] [Related]
25. Keynote review: histamine H3 receptor antagonists reach out for the clinic. Celanire S; Wijtmans M; Talaga P; Leurs R; de Esch IJ Drug Discov Today; 2005 Dec; 10(23-24):1613-27. PubMed ID: 16376822 [TBL] [Abstract][Full Text] [Related]
26. Nasal allergic response mediated by histamine H3 receptors in murine allergic rhinitis. Nakaya M; Fukushima Y; Takeuchi N; Kaga K Laryngoscope; 2005 Oct; 115(10):1778-84. PubMed ID: 16222194 [TBL] [Abstract][Full Text] [Related]
28. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. Zhao C; Sun M; Bennani YL; Gopalakrishnan SM; Witte DG; Miller TR; Krueger KM; Browman KE; Thiffault C; Wetter J; Marsh KC; Hancock AA; Esbenshade TA; Cowart MD J Med Chem; 2008 Sep; 51(17):5423-30. PubMed ID: 18683917 [TBL] [Abstract][Full Text] [Related]
29. Differences in pharmacological properties of histamine H(3) receptor agonists and antagonists revealed at two human H (3) receptor isoforms. Esbenshade TA; Krueger KM; Yao BB; Witte DG; Estvander BR; Baranowski JL; Miller TR; Hancock AA Inflamm Res; 2006 Apr; 55 Suppl 1():S45-6. PubMed ID: 16705378 [No Abstract] [Full Text] [Related]
30. Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity. Cowart M; Gfesser GA; Browman KE; Faghih R; Miller TR; Milicic I; Baranowski JL; Krueger KM; Witte DG; Molesky AL; Komater VA; Buckley MJ; Diaz GJ; Gagne GD; Zhou D; Deng X; Pan L; Roberts EM; Diehl MS; Wetter JM; Marsh KC; Fox GB; Brioni JD; Esbenshade TA; Hancock AA Biochem Pharmacol; 2007 Apr; 73(8):1243-55. PubMed ID: 17371699 [TBL] [Abstract][Full Text] [Related]
31. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity. Covel JA; Santora VJ; Smith JM; Hayashi R; Gallardo C; Weinhouse MI; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Pulley MD; Smith BM; Ren A; Suarez M; Frazer J; Edwards J; Hauser EK; Lorea J; Semple G; Grottick AJ J Med Chem; 2009 Sep; 52(18):5603-11. PubMed ID: 19722526 [TBL] [Abstract][Full Text] [Related]
32. Role of the Histamine H Schlicker E; Kathmann M Handb Exp Pharmacol; 2017; 241():277-299. PubMed ID: 27787717 [TBL] [Abstract][Full Text] [Related]
33. Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Hancock AA; Brune ME Expert Opin Investig Drugs; 2005 Mar; 14(3):223-41. PubMed ID: 15833055 [TBL] [Abstract][Full Text] [Related]
34. The evolution of histamine H₃ antagonists/inverse agonists. Lebois EP; Jones CK; Lindsley CW Curr Top Med Chem; 2011; 11(6):648-60. PubMed ID: 21261594 [TBL] [Abstract][Full Text] [Related]
35. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure. Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032 [TBL] [Abstract][Full Text] [Related]
36. Progress in the development of histamine H Łażewska D; Kieć-Kononowicz K Expert Opin Ther Pat; 2018 Mar; 28(3):175-196. PubMed ID: 29334795 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of histamine H3 receptor agonists and antagonists. Leurs R; Blandina P; Tedford C; Timmerman H Trends Pharmacol Sci; 1998 May; 19(5):177-83. PubMed ID: 9652190 [TBL] [Abstract][Full Text] [Related]
38. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists. Lorenzi S; Mor M; Bordi F; Rivara S; Rivara M; Morini G; Bertoni S; Ballabeni V; Barocelli E; Plazzi PV Bioorg Med Chem; 2005 Oct; 13(19):5647-57. PubMed ID: 16085419 [TBL] [Abstract][Full Text] [Related]
39. Non-imidazole histamine NO-donor H3-antagonists. Tosco P; Bertinaria M; Di Stilo A; Cena C; Fruttero R; Gasco A Farmaco; 2005; 60(6-7):507-12. PubMed ID: 15927183 [TBL] [Abstract][Full Text] [Related]
40. Histamine H(3) receptor (H(3)R) antagonists and inverse agonists in the treatment of sleep disorders. Broderick M; Masri T Curr Pharm Des; 2011; 17(15):1426-9. PubMed ID: 21476958 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]